Search
  • 網站搜尋
亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。
返回搜索結果

Plasma or Serum Marker and Process for Detection of Cancer


總結

Colorectal cancer (CRC) is one of the most common malignancies worldwide and the number of new CRC cases has been increasing rapidly since 1975. While 70% of CRC cases develop from sporadic adenomas or adenomatous polyps, early detection or surgical removal of polyps is believed to be one of the most effective preventive measures. However, traditional screening methods are invasive, costly of low predictive value or could result in low detection rates.

A new, single but effective method is invented for detection of cancer, even at early stage. It provides a Polymerase Chain Reaction (PCR) based process in the detection of serum or plasma marker RNA and DNA related to ß-catenin, which are differentially present in blood of normal, and pre-malignant or tumor-bearing patients. Accumulation of cytoplasmic and nuclear ß-catenin signaling is tightly associated with the genesis of a wide variety of tumors and has been implicated in the oncogenesis of colorectal cancer and other types of cancer.

The process comprises detecting blood serum or plasma RNA and/or DNA as a tool in the diagnosis, early detection, monitoring, treatment and population screening of neoplastic diseases at various progression and clinical stages. With an amount of blood sample as small as 2-5ml, this method already provides an effective and accurate test for colorectal and other types of cancer. Such a test can also be applied to other plasma or serum RNA and DNA that are encoded for ß-catenin associated proteins. It is also non-invasive and the accessibility of sample collections and sensitivity can be improved.


技術優勢

1. The marker is differentially present in blood of normal, and pre-malignant or tumor-bearing patients
2. The method has the capacity to detect polyps (a pre-malignant growth) can be as small as 4mm in diameter
3. The amount of blood sample required is small (2-5ml) and sample collection is through non-invasive, normal blood-drawing procedure
4. Low cost - reagent cost per test is around HK$30.


技術應用

- Eearly detection, diagnosis monitoring and population screening for cancer


附加資料

Patent Number: HK1079795A1
Application Number: HK2006102516A
Inventor: HSIAO WEN-LAUN WENDY | CESAR WONG SZE-CHUEN
Priority Date: 28 Jun 2002
Priority Number: HK1079795A1
Application Date: 24 Feb 2006
Publication Date: 26 Jun 2009
IPC Current: C07H002104 | C12Q000168
Assignee Applicant: The Hong Kong University of Science & Technology
Title: PLASMA OR SERUM MARKER AND PROCESS FOR DETECTION OF CANCER
Usefulness: PLASMA OR SERUM MARKER AND PROCESS FOR DETECTION OF CANCER


主要類別

診斷/治療


細分類別

癌症/腫瘤


申請日期

24 Feb 2006


申請號碼

Hong Kong 06102516.5


專利信息

Hong Kong HK1079795


ID號碼

TTC.PA.169


國家/地區

香港

欲了解更多信息,請點擊 這裡
Business of IP Asia Forum
桌面版